ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia
University of Cologne · Vita-Salute San Raffaele University · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
107
total citations
- FWCI
- 42.43
- Percentile
- 100%
- References
- 36
Citations per year
Authors
8Topics & keywords
Topics
Keywords
- Venetoclax
- Ibrutinib
- Medicine
- Oncology
- Alemtuzumab
- Internal medicine
- Interim
- Refractory (planetary science)
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- SSanofi
- GSGilead Sciences
- CCelgene
- VFVillum Fonden
- EHEuropean Hematology Association
- RPRegeneron Pharmaceuticals
- BBeiGene
- IIncyte
- CCelltrion
- NNNovo Nordisk
- ESEuropean Society for Medical Oncology
- NNNovo Nordisk Fonden
- SServier
- SOSwedish Orphan Biovitrum
- MMorphoSys
- OOctapharma
- LDLilly Deutschland
- GGenentech
- LOLoxo Oncology
- CCilag